Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morgane Cheminant

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Hematological Oncology|June 30, 2016
Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphomaColombe Saillard, Helene Guermouche, Coralie Derrieux, et al.
Bone Marrow Transplantation|July 6, 2022
Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiencyAmbroise Marçais, Nizar Mahlaoui, Bénédicte Neven, et al.
Leukemia|June 20, 2020
Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtypeAmbroise Marçais, Ludovic Lhermitte, Maria Artesi, et al.
Haematologica|October 15, 2020
Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficienciesThomas Pincez, Julie Bruneau, Laureline Berteloot, et al.
Blood Advances|September 30, 2025
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA GroupMarion Aymard, Morgane Cheminant, Roch Houot, et al.
Haematologica|August 16, 2023
Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life studyPierre-Edouard Debureaux, Nathalie Forgeard, Dikelele Elessa, et al.
Haematologica|December 26, 2015
Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA studyMorgane Cheminant, Coralie Derrieux, Aurore Touzart, et al.
Leukemia & Lymphoma|June 20, 2022
Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreakMilena Kohn, Tamim Alsuliman, Sylvain Lamure, et al.
Haematologica|May 11, 2023
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphomaAmandine Decroos, Morgane Cheminant, Julie Bruneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2023
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA StudyClémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Hematological Oncology|June 30, 2016
Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphomaColombe Saillard, Helene Guermouche, Coralie Derrieux, et al.
Bone Marrow Transplantation|July 6, 2022
Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiencyAmbroise Marçais, Nizar Mahlaoui, Bénédicte Neven, et al.
Leukemia|June 20, 2020
Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtypeAmbroise Marçais, Ludovic Lhermitte, Maria Artesi, et al.
Haematologica|October 15, 2020
Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficienciesThomas Pincez, Julie Bruneau, Laureline Berteloot, et al.
Blood Advances|September 30, 2025
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA GroupMarion Aymard, Morgane Cheminant, Roch Houot, et al.
Haematologica|August 16, 2023
Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life studyPierre-Edouard Debureaux, Nathalie Forgeard, Dikelele Elessa, et al.
Haematologica|December 26, 2015
Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA studyMorgane Cheminant, Coralie Derrieux, Aurore Touzart, et al.
Leukemia & Lymphoma|June 20, 2022
Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreakMilena Kohn, Tamim Alsuliman, Sylvain Lamure, et al.
Haematologica|May 11, 2023
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphomaAmandine Decroos, Morgane Cheminant, Julie Bruneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2023
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA StudyClémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, et al.
Pageof 8